- Home
- OTLK vs AFRI Comparison
OTLK vs AFRI Comparison
Compare OTLK & AFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLK | AFRI |
|---|---|---|
| Founded | 2010 | 1943 |
| Country | United States | Gibraltar |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.6M | 269.1M |
| IPO Year | 2016 | 2022 |
Fundamental Metrics
Financial Performance| Metric | OTLK | AFRI |
|---|---|---|
| Price | $0.66 | $11.05 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 21.2M | 16.0K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,146,123.00 | N/A |
| Revenue This Year | $1,430.98 | N/A |
| Revenue Next Year | $173.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $8.13 |
| 52 Week High | $2.54 | $11.90 |
Technical Indicators
Market Signals| Indicator | OTLK | AFRI |
|---|---|---|
| Relative Strength Index (RSI) | 37.15 | 59.93 |
| Support Level | $0.60 | $9.54 |
| Resistance Level | $0.94 | $11.83 |
| Average True Range (ATR) | 0.04 | 0.50 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 53.36 | 60.31 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About AFRI Forafric Global PLC
Forafric Global PLC is engaged in the production and sale of wheat flour, semolina, pasta, and couscous products. The company operates through the Soft Wheat, Durum Wheat, and Couscous & Pasta segments. Its main brands include MAYMOUNA and TRIA. It generates the majority of its revenue from the Soft Wheat segment.